Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study

Korte, Mario R.; Fieren, M. W. J. A.; Sampimon, Denise E.; Lingsma, Hester F.; Weimar, Willem; Betjes, Michiel G. H.

doi:10.1093/ndt/gfq362

Cited by 91 publications

(83 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tamoxifen, a drug clinically used to prevent and treat breast cancer, is effective in treating abnormal healing disorders. Of particular interest are several reports that describe the efficacy of tamoxifen in promoting regression of fibrosis not only in idiopathic retroperitoneal fibrosis, 9-11 but also in fibrosclerotic disorders such as desmoid tumors, 12,13 encapsulating peritoneal sclerosis, 14,15 sclerosing cervicitis, and fibrosing mediastinitis. 16 In addition to clinical evidence of fibrosis regression with tamoxifen treatment, in vitro studies also suggest that tamoxifen possesses antifibrotic properties.…”

mentioning

confidence: 99%

Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease

Dellê

Rocha

Cavaglieri

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Tamoxifen, a selective estrogen receptor modulator, has antifibrotic properties; however, whether it can attenuate renal fibrosis is unknown. In this study, we tested the effects of tamoxifen in a model of hypertensive nephrosclerosis (chronic inhibition of nitric oxide synthesis with L-NAME). After 30 days, treated rats had significantly lower levels of albuminuria as well as lower histologic scores for glomerulosclerosis and interstitial fibrosis than untreated controls. Tamoxifen was renoprotective despite having no effect on the sustained, severe hypertension induced by L-NAME. Tamoxifen prevented the accumulation of extracellular matrix by decreasing the expression of collagen I, collagen III, and fibronectin mRNA and protein. These renoprotective effects associated with inhibition of TGF-b1 and plasminogen activator inhibitor-1, and with a significant reduction in a-smooth muscle actin-positive cells in the renal interstitium. Furthermore, tamoxifen abrogated IL-1b-and angiotensin-II-induced proliferation of fibroblasts from both kidney explants and from the NRK-49F cell line. Tamoxifen also inhibited the expression of extracellular matrix components and the production and release of TGF-b1 into the supernatant of these cells. In summary, tamoxifen exhibits antifibrotic effects in the L-NAME model of hypertensive nephrosclerosis, likely through the inhibition of TGF-b1, suggesting that it may have therapeutic use in CKD treatment.

show abstract

mentioning

confidence: 99%

Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease

Dellê

Rocha

Cavaglieri

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Sua eficácia na diminuição de mortalidade foi demonstrada em séries de casos, 13 mas seus efeitos colaterais limitam seu uso, especialmente o risco aumentado de tromboembolismo, que é ainda maior em pacientes com insuficiência renal.…”

Section: Discussionunclassified

Sclerosing encapsulating peritonitis after peritoneal dialysis

Cestari¹,

Conti²,

Prats³

et al. 2013

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

“…10 Tamoxifen therapy may also reduce mortality rates. 11 Use of tamoxifen plus corticosteroids has also been reported in the literature. [12][13][14] In a series of 23 patients with peritoneal sclerosis, none of the 9 patients who received tamoxifen developed EPS, but 4 of the 14 patients who were not receiving tamoxifen treatment developed EPS.…”

Section: Discussionmentioning

confidence: 99%

Additive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis

Huddam¹,

Azak²,

Koçak³

et al. 2012

Renal Failure

View full text Add to dashboard Cite

Peritoneal dialysis (PD) is one of the commonly used choices of continuous renal replacement therapies. Peritoneal membrane is damaged by using solutions with lower biocompatibility, peritonitis episodes, and vintage of PD therapy. Encapsulating peritoneal sclerosis (EPS) is a rare complication of PD and is presented by progressive fibrosis of the peritoneum. Fibrous tissue entrapment of the intestine, leading to complete intestinal obstruction, is referred to as EPS, the most severe form of sclerosing peritonitis. EPS is irreversible fibrosis of the peritoneal membrane usually associated with high rates of morbidity and mortality. Preventive strategies are the best choice of treatment. Also there is no proven effective therapy for EPS; there are only small-sized trials. Herein we present a case of EPS who improved with everolimus plus tamoxifen therapy.

show abstract

Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study

Abstract: Tamoxifen treatment in EPS patients is associated with lower mortality and shows a trend to an increased multivariate-adjusted survival. This supports additional use of tamoxifen to treat patients with severe EPS.

Cited by 91 publications

References 43 publications

Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease

Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease

Sclerosing encapsulating peritonitis after peritoneal dialysis

Additive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis

Contact Info

Product

Resources

About